NATROX® Wound Care is an Inotec AMD brand. The specialist wound care company based in Cambridge, England was formed specifically to introduce new technologies to healthcare professionals around the world to promote faster and better healing to patients.
The company’s flagship product, NATROX® O₂ topical oxygen wound therapy, is positioned to become an integral part of global wound care treatment regimes. It was designed by the company’s founder to help his aging aunt who was long suffering from a painful non-healing venous leg ulcer. After much research, he learned oxygen was the secret to healing. He quickly set out to develop a product that could deliver oxygen to a wound without harmful chemicals or adding pressure to the frail skin surrounding the wound. The technology known as NATROX® O₂ was soon born.
In an effort to share this solution with others, NATROX® Wound Care was founded with a mission to transform the quality of life for anyone living with a chronic wound. Because, surely, there were others struggling to close a hard-to-heal wound. The company believes everyone deserves the chance to heal.
What is NATROX® O₂ Continuous Topical Oxygen Therapy
This small, wearable medical device uses the natural properties of oxygen to stimulate healing in previously non-healing wounds. It is non-invasive, comfortable, portable, and highly effective.
Ideal across all clinical and home care settings. It can be used during any phase of healing and works with nearly all standard secondary dressings. Lightweight and discreet, NATROX® O₂ gives patients complete freedom of movement.
Benefits of using NATROX® O₂ Continuous Topical Oxygen Therapy
Types of wounds to consider include:
NATROX® Wound Care
Ground Floor, Unit 7340 Building, 7300 Cambridge Research Park,
Waterbeach, Cambridge CB25 9PD UK
Tel: +44 (0)1223 661830
1350 4th Street Drive NW
Hickory, North Carolina
+1 (888) 354 9772
+1 (828) 484 6151 – Fax
21A, Jalan Hijauan 3
+60 7585 2205
This small, wearable medical device uses the natural properties of oxygen to stimulate healing in previously non-healing wounds. It is non-invasive, comfortable, portable, and highly effective. Ideal across all clinical and home care settings. It can be used during any phase of healing and works with nearly all standard secondary dressings. Lightweight and discreet, NATROX® O2 gives patients complete freedom of movement.
Patients in rural communities may have limited access to wound care; however, this may be mitigated by using a shared care approach. This study assessed the impact of a remote assessment and monitoring tool in combination with adjunctive continuous topical oxygen therapy (cTOT) in patients with diabetes and hard-toheal wounds.Download White Paper
NATROX® Wound Care, a leading innovator in wound management solutions, is pleased to announce the publication of a groundbreaking study in WOUNDS journal, highlighting the potential of NATROX® O₂ in managing late radiation tissue injury following Mohs surgery.
Exciting news in the realm of wound care! The Wound Healing Society has recently increased topical oxygen therapy to 'Level 1' evidence in its updated DFU treatment guidelines, signifying a significant leap in the field.
NATROX® Wound Care, a leading innovator in wound care technology including NATROX® O₂ topical oxygen therapy, is delighted to announce the Journal of Wound Care has published a new expert-led consensus on the practical, evidence-based use of topical oxygen therapy (TOT) across chronic wound care.
NATROX® Wound Care, a leading innovator in wound care solutions, is pleased to announce the Ministry of Food & Drug Safety (MFDS) has granted approval to ship and sell its groundbreaking product NATROX® O₂ topical oxygen therapy into South Korea. A newly added NATROX® distribution partner in South Korea, KOVE Inc., was instrumental in getting the product registered in its country. This milestone marks the first time patients in South Korea will access this leading-edge medical device, bringing new hope to those suffering from chronic wounds.
We’re thrilled to share some exciting news. NATROX® Wound Care has once again secured the prestigious FIRST place in the MedTech50 list, making it TWO consecutive first-place wins for our innovative startup!
NATROX® Wound Care, a leading innovator in wound care technology including NATROX® O₂ topical oxygen therapy, proudly announces the release of newly published expert recommendations on the use of topical oxygen therapy for wound healing¹. The updated guidelines endorse topical oxygen therapy (TOT) as an adjunct therapy in the treatment of diabetic foot ulcers (DFUs)¹. With its endorsement by leading experts in the field, this ground-breaking therapy is poised to transform the lives of millions of people worldwide, offering renewed hope for effective healing and improved quality of life.
NATROX® Wound Care is excited to announce that Dr. Windy Cole, DPM will join as Director of Global Medical Affairs. She joins at a critical juncture as the company increases product availability worldwide and seeks to develop new solutions to improve chronic wound patient outcomes. Dr. Cole will be responsible for developing and overseeing medical strategy, strengthening strategic partnerships among key opinion leaders (KOLs), and advancing clinical evidence to support industry recognition of advanced wound therapies.
A 2022 publication from the American Diabetes Association presents a clinical compendia on the latest evidence-based therapies for diabetic foot ulcers (DFUs).
NATROX® Wound Care, a leading provider of advanced wound care technology for the treatment of chronic wounds, is pleased to announce Health Technology Wales (HTW) has published Guidance advising the routine adoption of NATROX® O₂ for the treatment of chronic, non-healing and complex diabetic foot ulcers (DFUs).
Delphi participants reached a consensus on when to prescribe topical oxygen therapy (TOT). Experts recommend using TOT in diabetic foot ulcers (DFUs) and supported payer reimbursement for this therapy modality.
NATROX® Wound Care, an Inotec AMD brand, is pleased to announce it has ranked number one in the MedTech50, recognised as the UK’s most innovative medical technology creator for 2022. The Business Cloud award honours companies helping diagnose and treat conditions mainly in a clinical setting. It spotlights the top 50 UK firms blazing a trail by creating original technology for the healthcare and medical sectors.
NATROX® Wound Care expands into the digital arena with the launch of its new offering, NATROX® IQ. The advanced wound hub is a digital app designed specifically for wound care teams to help manage caseloads more effectively. Clinicians can achieve consistency when capturing and documenting patient wound data. Available now through distribution partners in Hong Kong and Malaysia, NATROX® IQ is designed to make wound documentation easier.
Abstract: Managing painful hard-to-heal leg ulcers is challenging with current therapeutic options. Wounds are prone to being hypoxic, and the subsequent pain is often related to hypoxia. Hyperbaric oxygen therapy (HBOT) is used to treat hard-to-heal leg wounds by delivering 100% oxygen at a pressure 2–3 times higher than atmospheric pressure...
NATROX® Wound Care is excited to announce the addition of Dr. Thomas Serena, MD FACS FACHM MAPWCA, who joins as Chief Medical Officer (CMO) effective immediately. The internationally recognised expert in the field of wound healing has been the lead or Principal Investigator in over 100 clinical trials. He has a vast knowledge of oxygen therapy and understands its positive impact on chronic wounds.
NATROX® Wound Care is delighted to announce the appointment of globally recognised wound care and biofilm expert, Dr. Gregory Schultz, as Chief Scientific Officer (CSO).
Inotec AMD Ltd. is pleased to announce it has been recently added as an approved supplier to the UK’s NHS Supply Chain and NHS Shared Business Services (NHS SBS). Known for its innovative technology in advanced medical devices, Inotec is the maker of NATROX® Oxygen Wound Therapy. Its addition marks the first time continuous topical oxygen therapy (cTOT) has been listed. This new category means NHS staff, publicly funded organisations, hospitals, and wound care clinics can easily prescribe this highly effective therapy.
Inotec AMD, manufacturer of NATROX® Oxygen Wound Therapy, is delighted to share newly published randomised controlled trial (RCT) results1. The trial involved 145 patients with previously non-healing diabetic foot ulcers (DFUs) and compared the effects of using standard care against a combination of standard care plus NATROX® Oxygen Wound Therapy. Patients completing the therapy experienced 71% greater healing rates and 73% greater reduction in wound size using NATROX®. These results offer hope to patients suffering from chronic wounds.